Among them, JAK kinase TYK2 might be the most promising therapeutic target towards VHL-loss ccRCC patients, since the overall survival of TYK2 high expression group was significantly higher than that of TYK2 low expression group in patients with VHL mutation. The gene discussed is TYK2; the disease is nonpapillary renal cell carcinoma.